Inhibrx Biosciences, Inc. (NASDAQ:INBX) Receives Average Rating of "Hold" from Brokerages

Key Points

• Analysts give Inhibrx an average rating of Hold from six brokerages (1 sell, 3 hold, 1 buy, 1 strong buy) with an average 12‑month price target of $150.
• Shares opened at $128.12, valuing the company at about $1.87 billion and trading well above its 50‑day and 200‑day moving averages (≈$80), inside a 52‑week range of $10.84 to $155.29.
• Inhibrx is a clinical‑stage biotech (lead candidate INBRX‑109) with negative recent earnings (Q1 EPS -$2.11, missing estimates) and analysts project FY EPS of -11.15, while institutional investors own roughly 82.46% of the stock.

Inhibrx Biosciences, Inc. (NASDAQ:INBX - Get Free Report) has received an average recommendation of "Hold" from the six brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $150.00.

A number of analysts have recently issued reports on INBX shares. Wall Street Zen upgraded shares of Inhibrx Biosciences from a "sell" rating to a "hold" rating in a research note on Saturday. Weiss Ratings reiterated a "sell (d)" rating on shares of Inhibrx Biosciences in a research note on Thursday, January 22nd. Lifesci Capital upgraded shares of Inhibrx Biosciences to a "strong-buy" rating in a research note on Friday, April 24th. Stifel Nicolaus started coverage on shares of Inhibrx Biosciences in a research note on Wednesday, April 8th. They set a "buy" rating and a $150.00 price objective on the stock. Finally, Zacks Research upgraded shares of Inhibrx Biosciences to a "hold" rating in a research note on Thursday, April 9th.

Inhibrx Biosciences Trading Up 0.1%

INBX opened at $128.12 on Wednesday. The firm has a market capitalization of $1.87 billion, a P/E ratio of -14.17 and a beta of 3.88. The firm's 50 day moving average is $80.33 and its 200-day moving average is $77.63. Inhibrx Biosciences has a 52-week low of $10.84 and a 52-week high of $155.29. The company has a quick ratio of 3.93, a current ratio of 3.93 and a debt-to-equity ratio of 12.58.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($2.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.08) by ($0.03). Analysts expect that Inhibrx Biosciences will post -11.15 EPS for the current fiscal year.

Institutional Trading of Inhibrx Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in INBX. Persistent Asset Partners Ltd bought a new stake in shares of Inhibrx Biosciences in the fourth quarter worth $27,000. Strs Ohio bought a new stake in shares of Inhibrx Biosciences in the first quarter worth $27,000. Public Employees Retirement System of Ohio bought a new stake in shares of Inhibrx Biosciences in the third quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Inhibrx Biosciences by 26.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 707 shares of the company's stock worth $56,000 after buying an additional 147 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of Inhibrx Biosciences by 71.9% in the third quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company's stock worth $64,000 after buying an additional 789 shares during the last quarter. Institutional investors own 82.46% of the company's stock.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company's proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company's lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.